替奈普酶用于急性缺血性卒中的溶栓治疗
本文系统检索并定性汇总了替奈普酶治疗缺血性卒中的已发表临床试验,包括与阿替普酶的随机对照、不同剂量比较及荟萃分析。荟萃分析(1585例随机患者)提示替奈普酶在大血管闭塞再通方面优于阿替普酶,3个月无残疾结局非劣效,且未增加症状性颅内出血或死亡。指南将静脉替奈普酶(0.25或0.4 mg/kg)列为二线选项,其中0.25 mg/kg推荐用于大血管闭塞。
要点
- 替奈普酶单次弹丸注射方便,0.5 mg/kg已获批用于STEMI。
- 卒中剂量0.25和0.4 mg/kg均被研究,0.25 mg/kg推荐用于大血管闭塞。
- 荟萃分析显示替奈普酶再通优于阿替普酶,3个月无残疾结局非劣效。
核心结论
- 荟萃分析提示替奈普酶在大血管闭塞再通方面优于阿替普酶,3个月无残疾结局非劣效,且未增加症状性颅内出血或死亡。
- 指南将静脉替奈普酶(0.25或0.4 mg/kg)列为卒中溶栓二线选项,0.25 mg/kg推荐用于大血管闭塞。
研究设计与样本
- 基于系统文献检索,定性汇总已发表的替奈普酶卒中临床试验,包括与阿替普酶的随机对照、不同剂量比较及荟萃分析。
- 纳入4项2期和1项3期随机对照试验与阿替普酶比较,以及其他2期剂量研究。
- 荟萃分析共纳入1585例随机患者。
主要发现
- 替奈普酶在大血管闭塞再通方面优于阿替普酶。
- 替奈普酶在3个月无残疾结局方面非劣效于阿替普酶。
- 替奈普酶未增加症状性颅内出血或死亡。
- 0.25和0.4 mg/kg剂量均被测试,未提示高剂量优势。
- 0.25 mg/kg基于一项2期试验显示再通和3个月结局优于阿替普酶。
关键数值与推荐
- 替奈普酶0.5 mg/kg已获批用于STEMI,30天死亡率等效且全身出血更少。
- 卒中指南将静脉替奈普酶0.25或0.4 mg/kg列为二线选项。
- 0.25 mg/kg推荐用于大血管闭塞。
临床怎么用
- 替奈普酶可作为急性缺血性卒中溶栓的二线选择,尤其大血管闭塞可考虑0.25 mg/kg。
- 单次弹丸注射方便使用。
- 需注意目前证据来自荟萃分析,尚未有单个试验前瞻性证明优效或非劣效。
局限性
- 无单个试验前瞻性证明替奈普酶在临床结局上的优效性或非劣效性。
- 正在进行的3期随机试验可能更好定义替奈普酶与阿替普酶的风险获益。
- 替奈普酶在>4.5小时时间窗、醒后卒中及联合血管内取栓的疗效尚待解答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tenecteplase is a fibrinolytic drug with higher fibrin specificity and longer half-life than the standard stroke thrombolytic, alteplase, permitting the convenience of single bolus administration. Tenecteplase, at 0.5 mg/kg, has regulatory approval to treat ST-segment-elevation myocardial infarction, for which it has equivalent 30-day mortality and fewer systemic hemorrhages. Investigated as a thrombolytic for ischemic stroke over the past 15 years, tenecteplase is currently being studied in several phase 3 trials. Based on a systematic literature search, we provide a qualitative synthesis of published stroke clinical trials of tenecteplase that (1) performed randomized comparisons with alteplase, (2) compared different doses of tenecteplase, or (3) provided unique quantitative meta-analyses. Four phase 2 and one phase 3 study performed randomized comparisons with alteplase. These and other phase 2 studies compared different tenecteplase doses and effects on early outcomes of recanalization, reperfusion, and substantial neurological improvement, as well as symptomatic intracranial hemorrhage and 3-month disability on the modified Rankin Scale. Although no single trial prospectively demonstrated superiority or noninferiority of tenecteplase on clinical outcome, meta-analyses of these trials (1585 patients randomized) point to tenecteplase superiority in recanalization of large vessel occlusions and noninferiority in disability-free 3-month outcome, without increases in symptomatic intracranial hemorrhage or mortality. Doses of 0.25 and 0.4 mg/kg have been tested, but no advantage of the higher dose has been suggested by the results. Current clinical practice guidelines for stroke include intravenous tenecteplase at either dose as a second-tier option, with the 0.25 mg/kg dose recommended for large vessel occlusions, based on a phase 2 trial that demonstrated superior recanalization and improved 3-month outcome relative to alteplase. Ongoing randomized phase 3 trials may better define the comparative risks and benefits of tenecteplase and alteplase for stroke thrombolysis and answer questions of tenecteplase efficacy in the >4.5-hour time window, in wake-up stroke, and in combination with endovascular thrombectomy.
引用
- Warach SJ, Dula AN, Milling TJ, et al. Tenecteplase Thrombolysis for Acute Ischemic Stroke. Stroke. 2020. PMID: 33045929. doi:10.1161/STROKEAHA.120.029749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。